A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Status:
Recruiting
Trial end date:
2022-12-19
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the effectiveness of fremanezumab as
compared to placebo for the preventive treatment of episodic migraine (EM).
Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to
placebo for the preventive treatment of EM, to evaluate the safety and tolerability of
Fremanezumab in the preventive treatment of EM and to evaluate the immunogenicity of
Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in
participants exposed to Fremanezumab.
The total duration of the study is planned to be up to 36 months.